2015 Annual Meeting on Women's Cancer®

March 26 - 31, 2015

David Parry, PhD

Global Price and Reimbursement Director
AstraZeneca
Alderley Park
Macclesfield United Kingdom SK10 4TF

Papers:
13 Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for post-progression PARP inhibitor therapy